ID: ALA123782

Max Phase: Preclinical

Molecular Formula: C25H19Cl2N3O2

Molecular Weight: 464.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc2c3c(c1)C(c1ccccc1)=N[C@@H](NC(=O)c1cc(Cl)cc(Cl)c1)C(=O)N3CC2

Standard InChI:  InChI=1S/C25H19Cl2N3O2/c1-14-9-16-7-8-30-22(16)20(10-14)21(15-5-3-2-4-6-15)28-23(25(30)32)29-24(31)17-11-18(26)13-19(27)12-17/h2-6,9-13,23H,7-8H2,1H3,(H,29,31)/t23-/m0/s1

Standard InChI Key:  CUTKMZSAEQAYIG-QHCPKHFHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 464.35

Molecular Weight (Monoisotopic): 463.0854

AlogP: 4.80

#Rotatable Bonds: 3

Polar Surface Area: 61.77

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.86

CX Basic pKa: 0.07

CX LogP: 5.51

CX LogD: 5.51

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.61

Np Likeness Score: -0.59

References

1. Pascal Y, Andrianjara CR, Auclair E, Avenel N, Bertin B, Calvet A, Féru F, Lardon S, Moodley I, Ouagued M, Payne A, Pruniaux MP, Szilagyi C..  (2000)  Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.,  10  (1): [PMID:10636238] [10.1016/s0960-894x(99)00573-9]

Source

Source(1):

• Scientific Literature